Evaluation of Safety and Tolerability of Long-term TEV-50717 (Deutetrabenazine) for Treatment of Tourette Syndrome in Children and Adolescents
- First Posted Date
- 2018-06-25
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 228
- Registration Number
- NCT03567291
- Locations
- 🇵🇱
Teva Investigational Site 060-1104, Gdansk, Poland
🇵🇱Teva Investigational Site 060-1102, Poznan, Poland
🇺🇦Teva Investigational Site 060-2003, Dnipropetrovsk, Ukraine
Fremanezumab Compassionate Use Program for Pediatric Patients
- Conditions
- First Posted Date
- 2018-05-29
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Registration Number
- NCT03539393
Study to Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Participants With Schizophrenia
- First Posted Date
- 2018-04-19
- Last Posted Date
- 2023-03-10
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 544
- Registration Number
- NCT03503318
- Locations
- 🇺🇸
Teva Investigational Site 14770, Marietta, Georgia, United States
🇺🇸Teva Investigational Site 14824, Atlanta, Georgia, United States
🇺🇸Teva Investigational Site 14779, Santa Ana, California, United States
Alternatives for Reducing Tics in Tourette Syndrome (TS): A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents
- First Posted Date
- 2018-03-02
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 119
- Registration Number
- NCT03452943
- Locations
- 🇺🇸
Teva Investigational Site 046-0125, Raleigh, North Carolina, United States
🇺🇸Teva Investigational Site 046-0106, Oklahoma City, Oklahoma, United States
🇩🇰Teva Investigational Site 046-0302, Herlev, Denmark
A Study to Test if Fremanezumab Reduces Headache in Participants With Posttraumatic Headache (PTH)
- First Posted Date
- 2017-11-20
- Last Posted Date
- 2022-12-13
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 87
- Registration Number
- NCT03347188
- Locations
- 🇺🇸
Teva Investigational Site 14119, Albany, New York, United States
🇺🇸Teva Investigational Site 14055, Dallas, Texas, United States
🇺🇸Teva Investigational Site 14064, Philadelphia, Pennsylvania, United States
An Efficacy and Safety Study of Fremanezumab in Adults With Migraine
- First Posted Date
- 2017-10-13
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 838
- Registration Number
- NCT03308968
- Locations
- 🇺🇸
Teva Investigational Site 14760, Decatur, Georgia, United States
🇺🇸Teva Investigational Site 14739, San Diego, California, United States
🇸🇪Teva Investigational Site 42054, Stockholm, Sweden
Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Interventions
- First Posted Date
- 2017-08-22
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 405
- Registration Number
- NCT03256695
- Locations
- 🇺🇸
Teva Investigational Site 14705, Chesterfield, Missouri, United States
🇺🇸Teva Investigational Site 14722, Greensboro, North Carolina, United States
🇺🇸Teva Investigational Site 14683, Pittsburgh, Pennsylvania, United States
A Study to Explore the Long-Term Safety and Efficacy of Fremanezumab (TEV-48125) for the Prevention of Cluster Headache
- First Posted Date
- 2017-04-11
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 275
- Registration Number
- NCT03107052
- Locations
- 🇺🇸
Teva Investigational Site 13812, Stamford, Connecticut, United States
🇺🇸Teva Investigational Site 13809, Raleigh, North Carolina, United States
🇺🇸Teva Investigational Site 13824, Philadelphia, Pennsylvania, United States
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
- First Posted Date
- 2017-02-14
- Last Posted Date
- 2022-12-14
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 391
- Registration Number
- NCT03052725
- Locations
- 🇺🇸
Teva Investigational Site 14651, Chicago, Illinois, United States
🇧🇪Teva Investigational Site 37083, Gent, Belgium
🇵🇱Teva Investigational Site 53399, Krakow, Poland
Study of the Effect of a 5-Day Regimen of Study Drug on Peripheral Stem Cell Mobilization in Healthy Participants
- First Posted Date
- 2017-01-23
- Last Posted Date
- 2022-12-13
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 1
- Registration Number
- NCT03029000
- Locations
- 🇺🇸
Teva Investigational Site 14024, San Antonio, Texas, United States
🇺🇸Teva Investigational Site 14025, La Jolla, California, United States
🇺🇸Teva Investigational Site 14030, Cincinnati, Ohio, United States